Loading…
What foreign portfolio investors (FPIs) and India's active equity funds bought and sold in Healthcare, month by month, and the companies the funds moved into and out of.
FPI figures: CDSL’s fortnightly sector report, equity. Latest fortnight 16–31 Oct 2026. Mutual funds: every active equity fund’s monthly portfolio, latest month both sides are in: October 2026.
Each side’s net buying in Healthcare as a percent of what it held in the sector, so the two compare on one scale. Above the line: bought more than sold.
Net buying by active equity funds in each company of the sector, at month-end prices (a price move is not buying), across the funds that disclosed both months. FPIs are reported by sector only, so there is no company split for them.
| Company | Net | Bar | Added / cut | Funds holding |
|---|---|---|---|---|
| Max Healthcare Institute Limited | +₹1,089 Cr | 31 / 14 | 83 | |
| Zydus Lifesciences Limited | +₹566 Cr | 32 / 4 | 52 | |
| Natco Pharma Limited | +₹562 Cr | 25 / 0 | 29 | |
| Dr. Reddy's Laboratories Limited | +₹475 Cr | 28 / 8 | 76 | |
| Biocon Limited | +₹457 Cr | 26 / 3 | 62 | |
| Sahajanand Medical Technologies Limited | +₹374 Cr | 8 / 0 | 8 | |
| Paras Healthcare Limited | +₹326 Cr | 11 / 0 | 11 | |
| Divi's Laboratories Limited | +₹269 Cr | 35 / 27 | 149 | |
| Anthem Biosciences Limited | +₹198 Cr | 15 / 6 | 48 | |
| Piramal Pharma Limited | +₹187 Cr | 12 / 10 | 39 |
| Company | Net | Bar | Added / cut | Funds holding |
|---|---|---|---|---|
| Mankind Pharma Limited | −₹669 Cr | 23 / 22 | 78 | |
| Aurobindo Pharma Limited | −₹422 Cr | 19 / 25 | 81 | |
| Glenmark Pharmaceuticals Limited | −₹298 Cr | 4 / 13 | 42 | |
| Sun Pharmaceutical Industries Limited | −₹221 Cr | 29 / 19 | 155 | |
| Symbiotec Pharmalab Limited | −₹133 Cr | 3 / 10 | 20 | |
| Alkem Laboratories Limited | −₹109 Cr | 9 / 6 | 47 | |
| Krishna Institute Of Medical Sciences Limited | −₹81.4 Cr | 8 / 14 | 51 | |
| Sanofi Consumer Healthcare India Limited | −₹66.1 Cr | 4 / 3 | 24 | |
| Ajanta Pharma Limited | −₹65 Cr | 8 / 11 | 63 | |
| Eris Lifesciences Limited | −₹63.9 Cr | 7 / 5 | 25 |
The sector’s share of all Indian equity each side holds, at the end of each quarter. Where funds sit heavier or lighter than foreign investors, and how that changed.
| Quarter end | Active funds | FPIs | Funds vs FPIs | Funds holding |
|---|---|---|---|---|
| Sep 2026 | 10.2% | 8.0% | +2.2 pts | 560 |
| Jun 2026 | 9.2% | 7.4% | +1.8 pts | 445 |
| Mar 2026 | 8.9% | 7.1% | +1.8 pts | 375 |
| Dec 2025 | 8.1% | 6.3% | +1.8 pts | 221 |
| Sep 2025 | 8.4% | 6.7% | +1.8 pts | 223 |
| Jun 2025 | 8.5% | 6.6% | +1.9 pts | 226 |
| Mar 2025 | 8.8% | 6.9% | +1.9 pts | 245 |
| Dec 2024 | 9.1% | 7.1% | +2.0 pts | 175 |
| Sep 2024 | 8.5% | 6.3% | +2.2 pts | 178 |
| Jun 2024 | 7.6% | 5.6% | +2.0 pts | 146 |
| Mar 2024 | 9.0% | 5.9% | +3.1 pts | 143 |
| Dec 2023 | 8.9% | 5.4% | +3.4 pts | 113 |
Plus: funds hold more of the sector than FPIs do, as a share of their equity. Grey fund counts: fewer funds in the data that quarter, so the funds’ weight is from a smaller sample.
From CDSL’s report, published twice a month: net investment in the fortnight and holdings at its end.
| Fortnight | Net investment | Bar | Holdings at the end |
|---|---|---|---|
| 16–31 Oct 2026 | −₹57 Cr | ₹5.28 L Cr | |
| 1–15 Oct 2026 | −₹5,497 Cr | ₹5.05 L Cr | |
| 16–30 Sep 2026 | +₹3 Cr | ₹5.28 L Cr | |
| 1–15 Sep 2026 | +₹2,114 Cr | ₹5.36 L Cr | |
| 16–31 Aug 2026 | +₹3,021 Cr | ₹5.45 L Cr | |
| 1–15 Aug 2026 | +₹2,910 Cr | ₹5.34 L Cr | |
| 16–31 Jul 2026 | +₹3,654 Cr | ₹5.33 L Cr | |
| 1–15 Jul 2026 | +₹4,101 Cr | ₹5.23 L Cr | |
| 16–30 Jun 2026 | +₹1,435 Cr | ₹5.07 L Cr | |
| 1–15 Jun 2026 | −₹4,501 Cr | ₹4.83 L Cr | |
| 16–31 May 2026 | +₹601 Cr | ₹4.83 L Cr | |
| 1–15 May 2026 | −₹418 Cr | ₹4.89 L Cr | |
| 16–30 Apr 2026 | −₹2,445 Cr | ₹4.63 L Cr | |
| 1–15 Apr 2026 | −₹4,481 Cr | ₹4.52 L Cr | |
| 16–31 Mar 2026 | −₹2,202 Cr | ₹4.44 L Cr | |
| 1–15 Mar 2026 | −₹2,436 Cr | ₹4.57 L Cr | |
| 16–28 Feb 2026 | +₹722 Cr | ₹4.72 L Cr | |
| 1–15 Feb 2026 | −₹1,051 Cr | ₹4.56 L Cr | |
| 16–31 Jan 2026 | −₹5,113 Cr | ₹4.39 L Cr | |
| 1–15 Jan 2026 | −₹1,049 Cr | ₹4.67 L Cr | |
| 16–31 Dec 2025 | −₹643 Cr | ₹4.7 L Cr | |
| 1–15 Dec 2025 | −₹2,351 Cr | ₹4.73 L Cr | |
| 16–30 Nov 2025 | +₹743 Cr | ₹4.87 L Cr | |
| 1–15 Nov 2025 | −₹2,526 Cr | ₹4.82 L Cr |
The latest 24 fortnights. Source: CDSL.